To date, significant advancement in treatment of ccRCC with VEGF targeted inhibitors, has provided a proof of principle that targeting HIF-α, an upstream regulator of VEGF, may result in significant therapeutic benefits [1,19,20]. This evidence concerns the gene VEGFA and nonpapillary renal cell carcinoma.